In non-small cell lung cancer models, it has been confirmed that inhibiting TIM-3 can reduce the infiltration of MDSCs in the tumor microenvironment, upregulate T cell activity, and enhance tumor immune response (60, 63). The gene discussed is HAVCR2; the disease is neoplasm.